SIOP Scale Best for Detecting Ototoxicity With Cisplatin Tx

Share this content:
SIOP Scale Best for Detecting Ototoxicity With Cisplatin Tx
SIOP Scale Best for Detecting Ototoxicity With Cisplatin Tx

THURSDAY, Dec. 15, 2016 (HealthDay News) -- The Society for Industrial and Organizational Psychology Ototoxicity Scale (SIOP) seems to be best for classifying ototoxicity in cisplatin-treated pediatric patients, according to a study published online Dec. 12 in the Journal of Clinical Oncology.

Kristin R. Knight, M.D., from the Oregon Health and Science University in Portland, and colleagues compared ototoxicity classification systems in participants aged 1 to 30 years with planned cisplatin-containing treatment. The testing audiologist and two central review audiologists assessed and graded audiologic results using the American Speech-Language-Hearing Association Ototoxicity Criteria (ASHA), Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE), and Brock Ototoxicity Grades (Brock). The SIOP was also used by one central reviewer.

The researchers found that the prevalence of any degree of ototoxicity varied from 40 to 56 percent, and severe ototoxicity varied from 7 to 22 percent at the end of treatment. SIOP detected significantly more ototoxicity than CTCAE (P = 0.004); Brock criteria identified significantly fewer patients with any or severe ototoxicity (P < 0.001). Ototoxicity was detected earlier with SIOP than other scales. For ASHA and Brock, agreement between central reviewers and the institutional audiologist was almost perfect, while the poorest agreement was seen for CTCAE.

"The SIOP scale may be superior to ASHA, Brock, and CTCAE scales for classifying ototoxicity in pediatric patients who were treated with cisplatin," the authors write. "Future studies should evaluate inter-rater reliability of the SIOP scale."

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »